1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 14 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.
Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Vancomycin-Resistant Enterococcus faecium Infections - Overview
- Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
- Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
- Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
- Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
- Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
- Featured News & Press Releases
- Nov 26, 2018: MicuRx enrolls first patient in a phase 2 clinical trial in U.S. for novel antibiotic, Contezolid Acefosamil
- Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4
- Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
- Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
- Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
- May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
- Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Gnubiotics Sciences SA, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MetalloBio Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sano Chemicals Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Seres Therapeutics Inc, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2022
- Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, 2022
- Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acurx Pharmaceuticals Inc
- Aphios Corp
- Arietis Corp
- Curza Global LLC
- Daiichi Sankyo Co Ltd
- Gnubiotics Sciences SA
- Hsiri Therapeutics LLC
- Karveel Pharmaceuticals
- MetalloBio Ltd
- MGB Biopharma Ltd
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- NovoBiotic Pharmaceuticals LLC
- Opal Biosciences Ltd
- Oragenics Inc
- QureTech Bio AB
- Rebiotix Inc
- Sano Chemicals Inc
- Sentinella Pharmaceuticals Inc
- Seres Therapeutics Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Wockhardt Ltd
